| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
4.26(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
773,642 |
| 52
Week Range: |
$23.21 - $33.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 581 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
35,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
10,417 |
15,666 |
48,238 |
96,962 |
| Total Sell Value |
$292,740 |
$454,291 |
$1,411,373 |
$2,911,362 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
3 |
6 |
8 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
• • – |
2019-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
180,965 |
|
- |
|
| Frates James M |
SVP, Alks Inc; CFO ALKS |
• • – |
2019-02-17 |
4 |
D |
$32.54 |
$28,473 |
D/D |
(875) |
44,691 |
|
- |
|
| Frates James M |
SVP, Alks Inc; CFO ALKS |
• • – |
2019-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
45,566 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2019-02-17 |
4 |
D |
$32.54 |
$23,624 |
D/D |
(726) |
44,559 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2019-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
45,285 |
|
- |
|
| Brown Iain Michael |
SVP Finance & CAO, Alks Inc. |
• • – |
2019-02-17 |
4 |
D |
$32.54 |
$23,722 |
D/D |
(729) |
28,038 |
|
- |
|
| Brown Iain Michael |
SVP Finance & CAO, Alks Inc. |
• • – |
2019-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
28,767 |
|
- |
|
| Pops Richard F |
Director and CEO, Alkermes plc |
• • – |
2019-02-16 |
4 |
D |
$32.54 |
$173,764 |
D/D |
(5,340) |
694,413 |
|
- |
|
| Pops Richard F |
Director and CEO, Alkermes plc |
• • – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,125 |
699,753 |
|
- |
|
| Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
• • – |
2019-02-16 |
4 |
D |
$32.54 |
$36,087 |
D/D |
(1,109) |
177,965 |
|
- |
|
| Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
• • – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,375 |
179,074 |
|
- |
|
| Hopkinson Craig C. |
SVP, Med Dev/Med Affairs, CMO |
• • – |
2019-02-16 |
4 |
D |
$32.54 |
$35,241 |
D/D |
(1,083) |
5,995 |
|
- |
|
| Hopkinson Craig C. |
SVP, Med Dev/Med Affairs, CMO |
• • – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,375 |
7,078 |
|
- |
|
| Frates James M |
SVP, Alks Inc; CFO ALKS |
• • – |
2019-02-16 |
4 |
D |
$32.54 |
$35,729 |
D/D |
(1,098) |
42,566 |
|
- |
|
| Frates James M |
SVP, Alks Inc; CFO ALKS |
• • – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,375 |
43,664 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2019-02-16 |
4 |
D |
$32.54 |
$36,054 |
D/D |
(1,108) |
42,785 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,375 |
43,893 |
|
- |
|
| Brown Iain Michael |
SVP Finance & CAO, Alks Inc. |
• • – |
2019-02-16 |
4 |
D |
$32.54 |
$26,846 |
D/D |
(825) |
26,267 |
|
- |
|
| Brown Iain Michael |
SVP Finance & CAO, Alks Inc. |
• • – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,375 |
27,092 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2019-02-01 |
4 |
AS |
$32.73 |
$32,730 |
I/I |
(1,000) |
0 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2019-02-01 |
4 |
OE |
$8.98 |
$8,980 |
I/I |
1,000 |
1,000 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2019-01-04 |
4 |
AS |
$30.00 |
$30,000 |
I/I |
(1,000) |
0 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2019-01-04 |
4 |
OE |
$8.98 |
$8,980 |
I/I |
1,000 |
1,000 |
|
- |
|
| Anstice David W |
Director |
• • – |
2018-12-12 |
4 |
S |
$35.56 |
$312,710 |
D/D |
(8,787) |
66,213 |
|
- |
|
| Anstice David W |
Director |
• • – |
2018-12-12 |
4 |
OE |
$8.98 |
$179,600 |
D/D |
20,000 |
71,213 |
|
- |
|
1496 Records found
|
|
Page 23 of 60 |
|
|
0.08 (0.34%) 
